marketing
Acting Like a Market Leader
Feedback from clients is the best gift a vendor can get.
Read the full storyAn example of how healthcare is changing
This week I had to pay a visit to my doctor’s office to get some antibiotics for a pesky ear infection. While I was waiting to see the doctor I was really surprised when a patient came out to the lobby and told the nurse “I don’t need any more x-rays because you people want to make money from my insurance company”.
Want to keep people engaged with your brand ? Update the content
Take a look at your web analytics, specifically how many people are returning visitors. Are you giving them a reason to come back or have you left the content on your product website unchanged ?
Social media and pharma: time to put it into perspective
I attended the #HCSM chat on Twitter last night and of course the number one topic was the FDA’s letter on the Facebook Share button to Novartis. Not only is this a bad preview of where the FDA is headed with social media it is clearly a indication that the FDA does not understand the Internet and how people use the Web for information. Social media is about sharing content
What is Web 3.0 and can it help pharma marketers ?
Web 3.0 is often called the intelligent or semantic Web. We have gone from an era of too little information to an era of too much information.
Don’t rely on blockbuster drugs anymore
Blockbuster drugs.
FDA Dislikes Novartis on Facebook: Biotech’s Latest Mishaps
The Burrill Report submits: The U.S. Food and Drug Administration notified Novartis ( NVS ) that information the drug maker has on Facebook about its cancer drug Tasigna is misleading because it makes claims of its efficacy, but fails to note any risks.
FDA Warns Novartis Over Use Of Facebook Widget
In the latest instance in which the FDA has raised concerns about the use of social media, Novartis was tagged by the agency for using Facebook widgets on a US web site that promotes its Tasigna medication chronic myeloid leukemia. The widget, for those unfamiliar, is a button that you can click info developed by Novartis, which Facebook users can share with others. In a July 29 letter , the FDA’s Division of Drug Marketing, Advertising and Communications chastises Novartis for failing to include risk info on the widgets while the shared content “inadequately” conveys info that implies Tasigna is superior to other meds.
Do consumers really want to have a conversation with a drug company ?
Some people are disappointed at the latest FDA notice to Novartis over a Facebook button on one of their website pages but some people like John Mack predicted the direction the FDA would take when it comes to social media integration. The key question that a lot of people fail to ask is “do patients want to have a conversation with a drug company?” From almost one year of qual and quant research plus other 3rd party research (i.e.
The passion of the DTC marketer
A career working for big pharma used to be highly desirable. MBA’s interns would line up for a chance to work in the marketing department for a summer and I myself interviewed a lot of candidates who wanted a work in the marketing department. However those days maybe coming to an end





